Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795593 | 0.97 | PARP1 (0.64) | PARP1HCAR2KMT2APDE10APARP2 | |
| SCHEMBL6795464 | 0.94 | PARP1 (0.63) | PARP1HCAR2KMT2APDE10APARP2 | |
| SCHEMBL30176852 | 0.91 | PARP1 (0.73) | PARP1HCAR2KMT2APDE10APARP2 | |
| SCHEMBL6798298 | 0.89 | PARP1 (0.60) | PARP1HCAR2KMT2APDE10APARP2 | |
| SCHEMBL30176876 | 0.88 | PARP1 (0.73) | PARP1HCAR2KMT2APDE10APARP2 | |
| SCHEMBL29764103 | 0.82 | PDE10A (0.74) | PARP1KMT2APDE10APARP2MAOB | |
| SCHEMBL11288070 | 0.82 | PDE10A (0.74) | PARP1KMT2APDE10APARP2MAOB | |
| SCHEMBL6798276 | 0.81 | PARP1 (0.57) | PARP1KMT2APDE10APARP2TNKS2 | |
| SCHEMBL6790215 | 0.81 | PARP1 (0.54) | PARP1KMT2APDE10APARP2TNKS2 | |
| SCHEMBL6794764 | 0.81 | PARP1 (0.60) | PARP1HCAR2PDE10APARP2TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885HCAR2 3453/4885KMT2A 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.